Dicycloplatin or DCP is a Phase I clinical cancer drug which is derived from carboplatin and 1,1-cyclobutane dicarboxylate.[1] It has higher solubility and higher stability in comparison with the carboplatin.[2]

See also


  1. Apps, M. G.; Choi, E. H. Y.; Wheate, N. J. (2015). "The state-of-play and future of platinum drugs". Endocrine-related Cancer. 22 (4): 219–233. doi:10.1530/ERC-15-0237. PMID 26113607.
  2. Yu JJ, Yang X, Song Q, Mueller MD, Remick SC (Jan 2014). "Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies". Anticancer Res. 34 (1): 455–63. doi:10.5414/CP201761. PMID 24403501.

This article is issued from Wikipedia - version of the 11/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.